Core Viewpoint - Abbott has announced a definitive agreement to acquire Exact Sciences for $105 per share, totaling approximately $21 billion, to enhance its position in the cancer diagnostics market [1][5][6]. Company Overview - Exact Sciences specializes in early cancer detection and personalized treatment support, offering a range of products that assist patients and healthcare providers throughout the cancer journey [3][11]. - The company is recognized for its innovative cancer screening and precision oncology diagnostics, including the Cologuard® test and Oncotype DX® [4][11]. Financial and Operational Details - The acquisition will add a new growth vertical to Abbott's existing high single-digit growth profile, positioning it to lead in the $60 billion U.S. cancer screening and precision oncology diagnostics market [7]. - Exact Sciences is projected to generate over $3 billion in revenue this year, with a high teens organic sales growth rate, which will contribute to Abbott's total diagnostics sales exceeding $12 billion annually post-acquisition [8][7]. Strategic Implications - The merger aims to accelerate innovation and expand access to cancer diagnostics, enabling earlier detection and improved management of cancer for millions of patients [2][5]. - Abbott's CEO emphasized the complementary strengths of both companies, aiming to tackle global cancer challenges together [5][6]. Future Outlook - The transaction is expected to close in the second quarter of 2026, pending shareholder and regulatory approvals [6]. - Following the acquisition, Exact Sciences will continue to operate from its Madison, Wisconsin location, with its CEO remaining in an advisory role to facilitate the transition [9].

Core Viewpoint - Exact Sciences Corp. has launched the Cancerguard test, a new multi-cancer early detection blood test that is now available in the United States as a laboratory-developed test [1] Group 1: Product Launch - Cancerguard is the first commercially available multi-cancer early detection (MCED) test that analyzes multiple biomarker classes [1] - The test aims to help detect a wide range of cancers, including those that are often undiagnosed until later stages [1]